BioNTech SE

See all company news

• (23.Sep.2021) Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
• (22.Sep.2021) Pfizer and BioNTech Expand Collaboration With U.S. To Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
• (20.Sep.2021) Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty, Spikevax and Vaxzevria for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively
• (20.Sep.2021) Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
• (17.Sep.2021) FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
• (16.Sep.2021) Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full Health Canada Approval for Individuals 12 Years and Older
• (14.Sep.2021) City of Hope Trial Is First to Test an Investigational COVID-19 Vaccine in Immunocompromised Bone Marrow Transplant and Cellular Therapy Patients With Blood Cancers
• (27.Aug.2021) Proof of Vaccination Must Now Include Proof of Booster
• (26.Aug.2021) Pfizer and BioNTech Announce Collaboration With Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
• (25.Aug.2021) Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY in Individuals 16 and Older
• (25.Aug.2021) FDA Approves COMIRNATY, the First COVID-19 Vaccine Approved by the Agency and the First COVID-19 Vaccine Brand Name Approved in the U.S
• (24.Aug.2021) FDA Approves First COVID-19 Vaccine Which Can Be Distributed by Global WholeHealth Partners Corp as US Anticipates Considerable Uptick in Vaccination Rates, as Stated in 8K Filing 06/15/21
• (23.Aug.2021) Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full U.S. FDA Approval for Individuals 16 Years and Older
• (18.Aug.2021) Pfizer/BioNTech Submit Data for COVID-19 Booster Shots
• (16.Aug.2021) Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
• (12.Aug.2021) Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
• (11.Aug.2021) BioNTech to Use COVID Vaccine Profits to “Expand and Accelerate” Pipeline
• (11.Aug.2021) BioNTech Says Booster Doses May Be More Effective Than a Modified COVID-19 Vaccine
• (04.Aug.2021) BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
• (03.Aug.2021) New European Supply Deals Show Pfizer and Moderna Have Increased COVID-19 Vaccine Prices
• (26.Jul.2021) Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria Vaccine, and the Set-Up of Manufacturing Infrastructures in Africa
• (26.Jul.2021) Mixing AZ and Pfizer COVID-19 Vaccines Increases Antibody Levels
• (26.Jul.2021) BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent
• (23.Jul.2021) Pfizer and BioNTech to Provide U.S. Government With an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
• (22.Jul.2021) Statement on BioNTech's Support for Flood-Hit Areas in North Rhine-Westphalia and Rhineland-Palatinate
• (21.Jul.2021) Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
• (19.Jul.2021) BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
• (16.Jul.2021) U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine
• (12.Jul.2021) 10 Million Doses of MRNA-Based COVID-19 Vaccine to Be Supplied to Taiwan Region
• (09.Jul.2021) Pfizer, BioNTech Eye US Approval for COVID-19 Booster Dose
• (21.Jun.2021) Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine - The Pfizer-BioNTech
• (21.Jun.2021) Takara Bio Enters into a License and Supply Agreement of RetroNectin with BioNTech Cell & Gene Therapies GmbH
• (18.Jun.2021) BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients With Advanced Melanoma
• (10.Jun.2021) Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
• (02.Jun.2021) Israel Finds a 'Probable Link' Between Pfizer Vaccine and Myocarditis Cases
• (01.Jun.2021) Daegu's Push to Secure Covid-19 Shots From Pfizer Causes Confusion
• (28.May.2021) First COVID-19 Vaccine Approved for Children Aged 12 to 15 in EU
• (28.May.2021) Pfizer and Biontech Receive First Authorization in European Union for Covid-19 Vaccine in Adolescents
• (27.May.2021) Exelead Helps Manufacture Pfizer-BioNTech Covid-19 Vaccine
• (25.May.2021) AZ, Pfizer/BioNTech COVID-19 Vaccines 'Highly Effective' Against Indian Variant
• (24.May.2021) Pfizer Initiates Study Exploring Coadministration of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
• (21.May.2021) BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG
• (20.May.2021) Pfizer and BioNTech to Supply the European Union With Up to 1.8 Billion Additional Doses of COMIRNATY
• (20.May.2021) Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of Their COVID-19 Vaccine
• (18.May.2021) BioNTech Broadens Management Board by Appointing Jens Holstein as CFO
• (18.May.2021) The Kingdom of Bahrain Allows Vaccination for Adolescents Aged 12 to 17, and a Booster Dose for Those Over Fifty
• (17.May.2021) Update on Stability of COMIRNATY: Longer Storage Possible
• (12.May.2021) Pfizer Asks UK's MHRA to Approve Its COVID-19 Vaccine in Adolescents
• (12.May.2021) Pfizer to Seek COVID-19 Vaccine Approval in Mexico for Children Aged 12-15
• (11.May.2021) BioNTech Announces First Quarter 2021 Financial Results and Corporate Update
• (10.May.2021) Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic
• (07.May.2021) Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
• (06.May.2021) Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
• (05.May.2021) Health Canada Authorizes Use of the Pfizer-BioNTech COVID-19 Vaccine in Children 12 to 15 Years of Age
• (05.May.2021) BioNTech on Course to Produce Three Billion Doses of Pfizer-Partnered COVID-19 Vaccine in 2021
• (05.May.2021) CSafe Global Providing Thermal Protection for COVID-19 Vaccine Shipments From BioNTech Facility
• (30.Apr.2021) Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY in the EU to Adolescents
• (30.Apr.2021) Pfizer's First Batch of Vaccines Against Covid Arrives in Brazil with 1 Million Doses
• (27.Apr.2021) Texas Biomed Shares Critical Work in Development of Pfizer COVID Vaccine
• (23.Apr.2021) Government of Canada Secures Vaccine Supply Beyond 2021
• (22.Apr.2021) Start of Production in Record Time: Evonik Delivers First Lipids from German Facility to BioNTech
• (19.Apr.2021) Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY
• (15.Apr.2021) New Clinical Study Shows JOYSBIO COVID-19 Neutralizing Antibody Rapid Test Nearly 98% Accurate in Verifying Antibodies After Vaccination
• (09.Apr.2021) Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents
• (01.Apr.2021) Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
• (31.Mar.2021) BioNTech Forecasts €9.8bn in Sales of Pfizer-Partnered COVID-19 Vaccine in 2021
• (31.Mar.2021) Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
• (30.Mar.2021) BioNTech Announces Full Year 2020 Financial Results and Corporate Update
• (29.Mar.2021) Single Pfizer/BioNTech Dose Induces Strong Immune Response to COVID-19
• (26.Mar.2021) EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
• (26.Mar.2021) BioNTech Provides Update on Vaccine Production Status at Marburg Manufacturing Site
• (18.Mar.2021) Turkey to Start Pfizer-BioNTech Testing, Inoculations to Follow
• (17.Mar.2021) EU Announces 'Top-Up' of Ten Million Pfizer/BioNTech Vaccines in Q2
• (11.Mar.2021) Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
• (09.Mar.2021) Patients Recovered From COVID-19 May Require Just One Dose of mRNA Vaccine
• (09.Mar.2021) Pfizer/BioNTech's COVID-19 Vaccine Neutralises Brazil Variant, Suggests Study
• (03.Mar.2021) Health Canada Allows More Flexible Storage and Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine
• (03.Mar.2021) Pfizer-BioNTech's COVID-19 Vaccine Arrives in Rwanda
• (02.Mar.2021) UK Study Finds Pfizer/BioNTech, AZ/Oxford Vaccines Reduce Severe COVID-19 in Older People
• (01.Mar.2021) Flowserve Supports Pfizer in the Production of COVID-19 Vaccine
• (27.Feb.2021) BioNTech and Fosun Pharma Jointly Announce the Arrival of the First Batch of COVID-19 MRNA Vaccine in Hong Kong and Macau
• (27.Feb.2021) South Korea Vaccinates 18,000 to Start Ambitious COVID-19 Campaign
• (26.Feb.2021) FDA Authorises Flexible Storage for Pfizer/BioNTech COVID-19 Vaccine
• (26.Feb.2021) The CPAC Meeting Outcome Regarding Pfizer's COVID-19 Vaccine
• (25.Feb.2021) Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
• (25.Feb.2021) Pfizer/BioNTech Vaccine Is 94% Effective After Second Dose, Major Real-World Study Finds
• (25.Feb.2021) AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine
• (25.Feb.2021) BioNTech and Fosun Pharma Receive Special Import Authorization in Macau for COVID-19 Vaccine
• (25.Feb.2021) Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine
• (23.Feb.2021) First Dose of Pfizer/BioNTech Vaccine Reduces COVID-19 Infection Risk by 70%
• (23.Feb.2021) Brazil Approves Pfizer's COVID-19 Shot, but Has None to Use
• (19.Feb.2021) Researchers Suggest Delaying Second Dose of Pfizer/BioNTech Jab to Protect More People
• (19.Feb.2021) Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
• (18.Feb.2021) Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
• (18.Feb.2021) South African Variant Reduces Antibody Levels Produced by Pifzer/BioNTech's COVID-19 Vaccine
• (17.Feb.2021) In Vitro Study Published in the New England Journal of Medicine Demonstrates Sera From Individuals Immunized With the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 With South African Variant Spike Mutations
• (17.Feb.2021) Pfizer and BioNTech to Supply the European Union With 200 Million Additional Doses of COMIRNATY
• (15.Feb.2021) First Pfizer Vaccine Doses Arrive in Australia
• (15.Feb.2021) First Batch of COVID-19 Vaccine Arrives in NZ
• (12.Feb.2021) Pfizer and BioNTech to Supply the United States With 100 Million Additional Doses of COVID-19 Vaccine
• (12.Feb.2021) Canada Negotiates Accelerated Delivery Schedule for Pfizer-BioNTech's COVID-19 Vaccine
• (11.Feb.2021) Evonik Strengthens Strategic Partnership with BioNTech on COVID-19 Vaccine
• (10.Feb.2021) Update on Vaccine Production at BioNTech's Manufacturing Site in Marburg
• (10.Feb.2021) TriRadial Solutions Recognized for Contributions to BioNTech COVID-19 Vaccine
• (09.Feb.2021) Health Canada Issues Label Change Authorization for Pfizer-BioNTech COVID-19 Vaccine
• (09.Feb.2021) EU Orders Another 300 Million Doses of Pfizer/BioNTech's COVID-19 Vaccine
• (08.Feb.2021) Pfizer and BioNTech Publish Data from in Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies That Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants
• (05.Feb.2021) Merck and BioNTech Extend Strategic Partnership Through Accelerated Supply of Urgently Needed Lipids
• (04.Feb.2021) MIG Funds Increases BioNTech Dividend Payments to a Record €600 Million
• (03.Feb.2021) South Korea Approves Special Import of Pfizer Vaccine
• (03.Feb.2021) COVAX Publishes First Interim Distribution Forecast
• (01.Feb.2021) Pfizer and BioNTech Publish Preclinical Data From Investigational COVID-19 Vaccine Program in Nature
• (29.Jan.2021) Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies' Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science
• (29.Jan.2021) Novartis Signs Initial Agreement To Provide Manufacturing Capacity For Pfizer-Biontech COVID19 Vaccine
• (28.Jan.2021) South Africa COVID-19 Variant 'Unlikely' to Reduce Efficacy of Pfizer/BioNTech Jab
• (27.Jan.2021) Sanofi To Provide Support To Biontech In Manufacturing Their Covid-19 Vaccine To Help Address Public Health Needs
• (27.Jan.2021) In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies That Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants
• (27.Jan.2021) Pfizer/BioNTech to Develop a Booster Dose for Their COVID-19 Vaccine
• (26.Jan.2021) Comirnaty Wins the Vaccine Approval Race in Hong Kong, Ahead of Leading Rivals
• (25.Jan.2021) BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
• (22.Jan.2021) Pfizer and BioNTech Reach Agreement With COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
• (21.Jan.2021) Proud to Have Participated in the Development of BioNTech's COVID-19 Vaccine
• (21.Jan.2021) Allergic Reactions Including Anaphylaxis After Receipt of 1st Dose of Pfizer-BioNTech COVID-19 Vaccine
• (21.Jan.2021) Aviva Pharmacy Provides Initial Doses of COVID-19 Vaccine
• (20.Jan.2021) Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies That Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
• (18.Jan.2021) Pfizer, BioNTech Temporarily Slow Down Shipments of COVID-19 Vaccine to EU
• (12.Jan.2021) BioNTech Boosts COVID-19 Vaccine Capacity and Aims to Deliver 2 Billion Doses in 2021
• (11.Jan.2021) Statement on Voluntary COVID-19 Vaccination for BioNTech Employees and Suppliers to Ensure Undisrupted Manufacturing and Distribution of COVID-19 Vaccine Doses
• (08.Jan.2021) Pfizer/BioNTech Vaccine Shown to Be Effective Against New COVID-19 Variants
• (08.Jan.2021) Statement Regarding European Commission's Proposal to Purchase Additional Doses of BioNTech-Pfizer Vaccine
• (08.Jan.2021) An in Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies That Neutralize SARS-CoV-2 With a Mutation Associated With Rapid Transmission
• (07.Jan.2021) BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
• (06.Jan.2021) WHO Advises Both Doses of Pfizer/BioNTech's COVID-19 Vaccine Within a 21-28 Day Schedule
• (05.Jan.2021) Apex Innovative Sciences Supports Three Major COVID-19 Vaccine Trials
• (04.Jan.2021) Pfizer/BioNTech to Offer COVID-19 Vaccine to Placebo Recipients
• (04.Jan.2021) ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial
• (31.Dec.2020) BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine
• (29.Dec.2020) Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY
• (28.Dec.2020) Introducing COMIRNATY, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute
• (25.Dec.2020) Mexico Starts Giving First Shots of Pfizer-BioNtech Vaccine
• (23.Dec.2020) Correction: Pfizer and BioNTech to Supply the U.S. With 100 Million Additional Doses of COVID-19 Vaccine
• (23.Dec.2020) COVID-19 Vaccine Developers Respond to New Strain
• (21.Dec.2020) Pfizer Seeks Preliminary Review on Covid-19 Vaccine
• (21.Dec.2020) Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
• (21.Dec.2020) Pfizer and BioNTech Receive CHMP Positive Opinion for Their COVID-19 Vaccine
• (19.Dec.2020) Pfizer and BioNTech Receive Conditional Marketing Authorization by Swissmedic for COVID-19 Vaccine
• (18.Dec.2020) Walgreens Begins Administration of Pfizer's COVID-19 Vaccine in Long-Term Care Facilities
• (17.Dec.2020) Saudi Arabia Begins Inoculating People with Pfizer COVID-19 Vaccines
• (17.Dec.2020) Novant Health Administers Its First COVID-19 Vaccine
• (17.Dec.2020) El Camino Health to Begin COVID-19 Vaccinations for Frontline Employees as Early as December 19
• (17.Dec.2020) St. Bernard Hospital Uses Ultra-Cold Freezers for Longer Storage of Coronavirus Vaccine
• (17.Dec.2020) Karmanos Cancer Institute and McLaren Health Care Receive First COVID-19 Vaccines to Protect Health Care Professionals
• (17.Dec.2020) Pfizer/BioNTech COVID-19 Vaccine Set for Roll-Out in Germany This Month
• (17.Dec.2020) UCHealth Deploys BioIntelliSense BioButton Vaccine Monitoring Solution to Health Care Workers Receiving COVID-19 Vaccine
• (16.Dec.2020) EU Fast-Tracks Review of Pfizer/BioNTech COVID-19 Vaccine
• (16.Dec.2020) BioNTech and Fosun Pharma to Supply China With mRNA-based COVID-19 Vaccine
• (15.Dec.2020) Seattle Children's Plans COVID-19 Vaccine Rollout
• (15.Dec.2020) Vaccination Clinic Begins Tuesday at MD Anderson
• (15.Dec.2020) Controlant Now Providing Monitoring and Supply Chain Visibility for Pfizer-BioNTech COVID-19 Vaccine Distribution and Storage
• (15.Dec.2020) CSACI Statement on Potential Adverse Reactions to COVID-19 Vaccines
• (14.Dec.2020) Pfizer and BioNTech Provide Data From German Phase 1/2 Study Further Characterizing Immune Response Following Immunization With Lead COVID-19 Vaccine Candidate BNT162b2
• (13.Dec.2020) COVID-19 Vaccine Delivery and Distribution Statement from MD Anderson
• (12.Dec.2020) U.S. CDC Committee of Independent Health Experts Recommends Vaccination With Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older
• (12.Dec.2020) Mexico Approves Emergency Use of Pfizer's COVID-19 Vaccine
• (11.Dec.2020) Tampa General Hospital Is Preparing to Accept the First Shipment of COVID-19 Vaccine
• (11.Dec.2020) Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
• (10.Dec.2020) Children's Health Defense Calls for More Study of Pfizer COVID Vaccine for Seniors and Blacks in Advance of Emergency Use Authorization (EUA) in These Populations
• (10.Dec.2020) Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S
• (10.Dec.2020) UK Regulator Warns of Allergic Reactions to Pfizer/BioNTech Vaccine
• (10.Dec.2020) Pfizer and BioNTech Announce Publication of Results From Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in the New England Journal of Medicine
• (10.Dec.2020) Saudi Registers Pfizer COVID-19 Vaccine for Import, Use - SPA
• (09.Dec.2020) Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
• (09.Dec.2020) FDA Briefing Document Paves the Way for Pfizer/BioNTech COVID-19 Vaccine Approval
• (09.Dec.2020) Statement Regarding Cyber Attack on European Medicines Agency
• (08.Dec.2020) First Doses of Pfizer/BioNTech Vaccine Administered in the UK on 'V-Day'
• (07.Dec.2020) Connecticut Pathologist Offers to Verify Pfizer Vaccine Efficacy for FDA Evaluation if Pfizer Is Unable to Perform the Necessary Tests
• (07.Dec.2020) Canada to Receive Early Delivery of Pfizer-BioNTech COVID-19 Vaccine
• (04.Dec.2020) Bahrain Becomes Second Country to Approve Pfizer COVID-19 Vaccine
• (03.Dec.2020) WHO Set to Review Pfizer/BioNTech COVID-19 Vaccine for Emergency Use Listing
• (02.Dec.2020) Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
• (01.Dec.2020) Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
• (25.Nov.2020) BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lead MRNA COVID-19 Vaccine BNT162b2 in China
• (25.Nov.2020) BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
• (24.Nov.2020) FDA Sets 10 December Date for Pfizer's COVID-19 Vaccine Meeting
• (23.Nov.2020) UK Could Approve Pfizer's COVID-19 Vaccine This Week
• (20.Nov.2020) Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
• (20.Nov.2020) Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate
• (18.Nov.2020) Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
• (18.Nov.2020) QIAGEN Collaborates With BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
• (17.Nov.2020) Korean Pharma Struggle to Catch Up With Multinationals in Covid-19 Race
• (16.Nov.2020) Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness
• (16.Nov.2020) BioNTech and Fosun Pharma Receive Approval to Commence COVID-19 Vaccine Candidate BNT162b2 Trial in China
• (11.Nov.2020) Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate Against COVID-19
• (10.Nov.2020) BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
• (10.Nov.2020) NHS Asked to 'Ready' Itself to Provide Pfizer's COVID-19 Vaccine
• (09.Nov.2020) Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
• (28.Oct.2020) Pfizer CEO Says COVID-19 Vaccine Efficacy Data Could Come 'Soon'
• (23.Oct.2020) MIG Fund with Record Distribution After the Sale of a Further Quarter of Its Shares in BioNTech
• (20.Oct.2020) Pfizer and BioNTech Initiate Trials of Covid-19 Vaccine in Japan
• (19.Oct.2020) Pfizer CEO Pushes Back COVID-19 Vaccine Submission to November
• (14.Oct.2020) Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead MRNA Vaccine Candidate BNT162b2 Against COVID-19
• (09.Oct.2020) Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2
• (08.Oct.2020) Joining forces against SARS-CoV-2
• (06.Oct.2020) BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
• (30.Sep.2020) BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from MRNA-Based Vaccine Candidate BNT162b1 Against SARS-CoV-2
• (30.Sep.2020) Viromers Suitable as Carrier Systems for Gene-Based Treatment of Inflammatory Diseases
• (29.Sep.2020) Researchers Call on Pfizer to Delay COVID-19 Vaccine Application